Virosomal influenza vaccine: A safe and effective influenza vaccine with high efficacy in elderly and subjects with low pre-vaccination antibody titers

Virus Research

Volumn 103, Issue 1-2, 2004, Pages 139-145

  De Bruijn, I A ^a   Nauta, J ^a   Gerez, L ^a   Palache, A M ^a  

^a Solvay Pharmaceuticals Inc   (Netherlands)

Author keywords

Efficacy; Influenza vaccine; Reactogenicity; Safety; Virosomes

Indexed keywords

INFLUENZA VACCINE;

ANTIBODY TITER; BLOOD SAMPLING; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HEADACHE; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INJECTION PAIN; MALAISE; MYALGIA; PRIORITY JOURNAL; SEROLOGY; SKIN INDURATION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, VIRAL; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED; TREATMENT OUTCOME; VACCINATION; VACCINES, VIROSOME;

EID: 2442702944     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2004.02.026     Document Type: Conference Paper

References (27)

1. Ahmed A.H., Nicholson K.G., Nguyen-Van-Tam J.S. Reduction in mortality associated with influenza vaccine during 1989-90 epidemic. Lancet. 346:1995;591-595
2. Al-Khayatt R., Jennings R., Potter C.W. Interpretation of responses and protective levels of antibody against attenuated influenza A viruses using singel radial haemolysis. J. Hyg. Camb. 92:1984;301-312
3. Arkema A., Huckriede A., Schoen P., Wilschut J., Daemen T. Induction of cytotoxic T lymphocyte activity by fusion-active peptide-containing virosomes [in process citation]. Vaccine. 18:2000;1327-1333
4. Beyer W.E., de Bruijn I.A., Palache A.M., Westendorp R.G., Osterhaus A.D. Protection against influenza after annually repeated vaccination: a meta-analysis of serologic and field studies. Arch. Intern. Med. 159:1999;182-188
5. Beyer, W.E.P., 2002. Clinical Expert Report-Virosomal Subunit Influenza Vaccine. In file Solvay Pharmaceuticals, 28 March.
6. Beyer W.E.P., Palache A.M., Kerstens R., Masurel N. Gender differences in local and systemic reactions to inactivated influenza vaccine, established by a meta-analysis of fourteen independent studies. Eur. J. Clin. Microbiol. Infect. Dis. 15:1996;65-70
7. Beyer W.E.P., Palache A.M., Osterhaus A.D.M.E. Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus or split vaccines. A review and meta-analysis of the literature. Clin. Drug Invest. 15:1998;1-12
8. Bungener L., Huckriede A., Wilschut J., Daemen T. Delivery of protein antigens to the immune system by fusion-active virosomes: a comparison with liposomes and ISCOMs. Biosci. Rep. 22:2002a;323-338
9. Bungener L., Serre K., Bijl L., Leserman L., Wilschut J., Daemen T., Machy P. Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine. 20:2002b;2287-2295
10. Committee for Proprietary Medicinal Products, 1997. Note for guidance on harmonization of requirements for influenza vaccines, CPMP/BWP/214/96.
11. Cryz S.J., Que J.U., Gluck R. A virosome vaccine antigen delivery system does not stimulate an antiphospholipid antibody response in humans. Vaccine. 14:1996;1381-1383
12. Dowdle W.R., Coleman M.T., Mostow S.R., Kaye H.s., Schoenbaum S.C. Inactivated influenza vaccines. 2. Laboratory indices of protection. Postgrad. Med. J. 49:1973;159-163
13. Ginaldi L., De Martinis M., D'Ostilio A., Marini L., Loreto M.F., Corsi M.P., Quaglino D. The immune system in the elderly: I. Specific humoral immunity. Immunol. Res. 20:1999a;101-108
14. Ginaldi L., De Martinis M., D'Ostilio A., Marini L., Loreto M.F., Martorelli V., Quaglino D. The immune system in the elderly: II. Specific cellular immunity. Immunol. Res. 20:1999b;109-115
15. Gross P.A., Hermogenes A.W., Sacks H.S., Lau J., Levandowski R.A. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann. Intern. Med. 123:1995;518-527
16. Hierholzer J.C., Suggs M.T., Hall E.C. Standardized viral hemagglutination and hemagglutination-inhibition tests. II. Description and statistical evaluation. Appl. Microbiol. 18:1969;824-833
17. Hirota Y., Kaji M., Ide S., Kaijwara J., Kataoka K., Goto S., Oka T. Antibody efficacy as a keen index to evaluate influenza vaccine effectiveness. Vaccine. 15:1997;962-967
18. Monto, A.S., 1996. The clinical efficacy of influenza vaccination. Pharmacoeconomics (Suppl. 3) 16-25.
19. Monto, A.S., Ohmit, S.E., 1996. Effectiveness evaluation of inactivated influenza vaccines: methods and results. In: Brown, L.E., Hampson, A.W., Webster, R.G. (Eds.), Options for the Control of Influenza III. Proceedings of the Third International Conference on Options for the Control of Influenza, Cairns, Australia, 4-9 May 1996. Excerpta Medica, Amsterdam, Lausanne, New York, Oxford, Shannon, Tokyo, pp. 93-96.
20. Nguyen-Van-Tam, J.S., Ahmed, A.H., Nicholson, K.G., Pearson, J.C.G., 1996. Reduction in hospital admissions for pneumonia, influenza, bronchitis and emphysema associated with influenza vaccine during the 1989-90 epidemic in Leicestershire, UK. In: Brown, L.E., Hampson, A.W., Webster, R.G. (Eds.), Options for the Control of Influenza III. Proceedings of the Third International Conference on Options for the Control of Influenza, Cairns, Australia, 4-9 May. Excerpta Medica, pp. 107-112.
21. Nichol, K.L., 1996. Clinical effectiveness of influenza vaccine in community-living seniors. In: Brown, L.E., Hampson, A.W., Webster, R.G. (Eds.), Options for the Control of Influenza III. Proceedings of the Third International Conference on Options for the Control of Influenza, Cairns, Australia, 4-9 May 1996. Excerpta Medica, Amsterdam, Lausanne, New York, Oxford, Shannon, Tokyo, pp. 119-122.
22. Nichol K.L., Margolis K.L., Wouremna J., Von Sternberg T. Effectivenss of influenza vaccine in the elderly. Gerontology. 42:1996;274-279
23. Palache A.M., Beyer W.E.P., Lüchters G., Völker R., Sprenger M.J.W., Masurel N. Influenza vaccines the effect of vaccine dose on antibody response in primed populations during the ongoing interpandemic period. A review of the literature. Vaccine. 11:1993;892-908
24. Palmer, D.F., Dowdle, W.R., Coleman, M.T., Schild, G.C., Hemagglutination-inhibition test. In: Welfare, P.H.S. (Ed.), Advanced Laboratory Technicals for Immunological Diagnostic, U.S. Department Health, Atlanta pp. 25-62.
25. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine. 19:2001;2673-2680
26. Potter C.W., Oxford J.S. Determinants of immunity to influenza infection in man. Br. Med. Bull. 35:1979;69-75
27. Pregliasco F., Mensi C., Serpilli W., Speccher L., Masella P., Belloni A. Immunogenicity and safety of three commercial influenza vaccines in institutionalized elderly. Aging (Milano.). 13:2001;38-43